Urgency in overactive bladder: Translating experimental data into clinical practice

Drugs of Today

Volumn 44, Issue 5, 2008, Pages 381-389

  Wyndaele, Jean Jacques ^a   De Wachter, Stefan ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

CONSTIPATION; CYSTOMETRY; DRUG EFFICACY; DRUG SAFETY; ELECTROSTIMULATION THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; OVERACTIVE BLADDER; PARASYMPATHETIC INNERVATION; PHARMACODYNAMICS; PSYCHOLOGICAL ASPECT; REVIEW; URINARY URGENCY; XEROSTOMIA; MICTURITION; PATHOPHYSIOLOGY;

HUMANS; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 51649108362     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.5.1215723     Document Type: Review

References (66)

1. Tubaro, A. Defining overactive bladder: Epidemiology and burden of disease. Urology 2004, 64(6, Suppl. 1): 2-6.
2. Tikkinen, K.A., Tammela, T.L., Rissanen, A.M., Valpas, A., Huhtala, H., Auvinen, A. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS ONE 2007, 2(2): e195
3. Chapple, C.R., Artibani, W., Cardozo, L.D. et al. The role of urinary urgency and its mea surement in the overactive bladder symptom syndrome: Current concepts and future prospects. BJU Int 2005, 95(3): 335-40.
4. Abrams, P., Cardozo, L., Fall, M. et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21(2): 167-78.
5. Chapple, C.R., Wein, A.J. The urgency of the problem and the problem of urgency in the overactive bladder. BJU Int 2005, 95(3): 274-5.
6. Haylen, B.T., Chetty, N., Logan, V., Schulz, S., Verity, L., Law, M., Zhou, J. Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity? Int Urogynecol J Pelvic Floor Dysfunct 2007, 18(2): 123-8.
7. Blaivas, J.G. Overactive bladder and the definition of urgency. Neurourol Urodyn 2007, 26(6): 757-8.
8. Brading, A.F. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: Current concepts and future prospects. BJU Int 2005, 96(3): 441-2.
9. Brubaker, L. Urgency: The cornerstone symptom of overactive bladder. Urology 2004, 64(6, Suppl. 1): 12-6.
10. Lincoln, J., Burnstock, G. Autonomic innervation of the urinary bladder and urethra. In: Nervous Control of the Urogenital System. Maggi, C.A. (Ed.). Harwood Academic Publishers, London, 1993, 89-131.
11. Uemura, E., Fletcher, T.F., Bradley, W.E. Distribution of lumbar and sacral afferent axons in submucosa of cat urinary bladder. Anat Rec 1975, 183(4): 579-88.
12. Gabella, G., Davis, C. Distribution of afferent axons in the bladder of rats. J Neurocytol 1998, 27(3): 141-55.
13. Wiseman, O.J., Brady, C.M., Hussain, I.F., Dasgupta, P., Watt, H., Fowler, C.J., Landon, D.N. The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia. J Urol 2002, 168(5): 2040-5.
14. Wiseman, O.J., Fowler, C.J., Landon, D.N. The role of the human bladder lamina propria myofibroblast. BJU Int 2003, 91(1): 89-93.
15. Yossepowitch, O., Gillon, G., Baniel, J., Engelstein, D., Livne, P.M. The effect of cholinergic enhancement during filling cystometry: Can edrophonium chloride be used as a provocative test for overactive bladder? J Urol 2001, 165(5): 1441-5.
16. Tyagi, S., Tyagi, P., Van-le, S., Yoshimura, N., Chancellor, M.B., de Miguel, F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 2006, 176(4, Pt. 1): 1673-8.
17. Hedge, S. Muscarinic receptors: From basic research to therapeutics. Br J Pharmacol 2006, 147(Suppl. 2): S80-7.
18. Cruz, F. Vanilloid receptor and detrusor instability. Urology 2002, 59(5, Suppl. 1): 51-60.
19. Ferguson, D.R., Kennedy, I., Burton, T.J. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - A possible sensory mechanism? J Physiol 1997, 505(Pt. 2): 503-11.
20. Cockayne, D.A., Hamilton, S.G., Zhu, Q.M. et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3- deficient mice. Nature 2000, 407(6807): 1011-5.
21. Rong, W., Spyer, K.M., Burnstock, G. Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder. J Physiol 2002, 541(Pt. 2): 591-600.
22. Yoshimura, N., Seki, S., Chancellor, M.B., de Groat, W.C., Ueda, T. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology 2002, 59(5, Suppl. 1): 61-7.
23. Lazzeri, M., Beneforti, P., Spinelli, M., Zanollo, A., Barbagli, G., Turini, D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: A randomized placebo controlled study. J Urol 2000, 164(3, Pt. 1): 676-9.
24. Silva, C., Silva, J., Castro, H. et al. Bladder sensory desensitization decreases urinary urgency. BMC Urol 2007, 7: 9.
25. De Wachter, S., Wyndaele, J.J. Intravesical oxybutynin: A local anesthetic effect on bladder C afferents. J Urol 2003, 169(5): 1892-5.
26. De Laet, K., De Wachter, S., Wyndaele, J.J. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: New insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006, 25(2): 156-61.
27. de Groat, W.C. Integrative control of the lower urinary tract: Preclinical perspective. Br J Pharmacol 2006, 147(Suppl. 2): S25-40.
28. Andersson, K.E., Wein, A. Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004, 56(4): 581-631.
29. De Wachter, S., Wyndaele, J.J. How sudden is a compelling desire to void? An observational cystometric study on the suddenness of this sensation. BJU Int 2008, 101(8): 1000-3.
30. Wyndaele, J.J., Van Meet, T.D., De Wachter, S. Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J Urol 2004, 172(5, Pt. 1): 1915-8.
31. De Wachter, S., Wyndaele, J.J. Frequency-volume charts: A tool to evaluate bladder sensation. Neurourol Urodyn 2003, 22(7): 638-42.
32. Naoemova, I., De Wachter, S., Wuyts, F.L., Wyndaele, J.J. Do sensation-related bladder diaries differ between patients with urodynamically confirmed and non-objectivised urinary incontinence? Int Urogynecol J Pelvic Rloor Dysfunct 2008, 19(2): 213-6.
33. Cardozo, L., Dixon, A. Increased warning time with darifenacin: A new concept in the management of urinary urgency. J Urol 2005, 173(4): 1214-8.
34. Carson, C.C., Segura, J.W., Osborne, D.M.. Evaluation and treatment of the female urethral syndrome. J Urol 1980, 124(5): 609-10.
35. Hafner, R.J., Stanton, S.L., Guy, J. A psychiatric study of women with urgency and urgency incontinence. Br J Urol 1977, 49(3): 211-4.
36. Klevmark, B. Hyperactive neurogenic bladder studied with physiological filling rates. Scand J Urol Nephrol 1981, 60(Suppl.): 55-6.
37. Diggs, C., Meyer, W.A., Langenberg, P., Greenberg, P., Horne, L., Warren, J.W. Assessing urgency in interstitial cystitis/painful bladder syndrome. Urology 2007, 69(2): 210-4.
38. Greenberg, P., Brown, J., Yates, T., Brown, V., Langenberg, P., Warren, J.W. Voiding urges perceived by patients with interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 2008, 27(4): 287-90.
39. Digesu, G.A., Khullar, V., Panayi, D., Calandrini, M., Gannon, M., Nicolini, U. Should we explain lower urinary tract symptoms to patients? Neurourol Urodyn 2007, Epub ahead of print.
40. Starkman, J.S., Dmochowski, R.R. Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn 2008, 27(1): 13-21.
41. Anderson, R.U., Mobley, D., Blank, B., Saltzstein, D., Susset, J., Brown, J.S., OROS Oxybutynin Study Group. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161(6): 1809-12.
42. Van Kerrebroeck, P., Kreder, K., Jonas, U., Zinner, N., Wein, A., Tolterodine Study Group. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57(3): 414-21.
43. Abrams, P., Freeman, R., Anderstrom, C., Mattiasson, A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998, 81(6): 801-10.
44. Appell, R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997, 50(6A, Suppl.): 90-6.
45. Lee, J.G., Hong, J.Y., Choo, M.S. et al. Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 2002, 9(5): 247-52.
46. Appell, R.A., Sand, P., Dmochowski, R. et al. Overactive bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study. Mayo Clin Proc 2001, 76(4): 358-63.
47. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004, 45(4): 420-9.
48. 3-selective receptor antagonist. BJU Int 2005, 95(4): 580-6.
49. 3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005, 23(4): 248-52.
50. Cardozo, L., Lisec, M., Millard, R. et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172(5, Pt. 1): 1919-24.
51. Chapple, C.R., Arano, P., Bosch, J.L., De Ridder, D., Kramer, A.E., Ridder, A.M. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004, 93(1): 71-7.
52. Chapple, C.R., Rechberger, T., Al-Shukri, S., Meffan, P., Everaert, K., Huang, M., Ridder, A., YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93(3): 303-10.
53. Zinner, N., Gittelman, M., Harris, R., Susset, J., Kanelos, A., Auerbach, S., Trospium Study Group. Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial. J Urol 2004, 171(6, Pt. 1): 2311-5.
54. Halaska, M., Ralph, G., Wiedemann, A., Primus, G., Ballering-Brühl, B., Höfner, K., Jonas, U. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003, 20(6): 392-9.
55. Hashim, H., Abrams, P. Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations. Drugs 2004, 64(15): 1643-56.
56. Jünemann, K.P., Al-Shukri, S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: A double-blind, placebo-controlled, multicentre clinical trial. Neurourol Urodyn 2000, 19(4): 488-90.
57. Roxburgh, C., Cook, J., Dublin, N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003190. DOI: 10.1002/14651858. CD003190.pub4.
58. Robinson, D., Cardozo, L., Terpstra, G., Bolodeoku, J., Tamsulosin Study Group. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007, 100(4): 840-5.
59. Wang, A.C., Chih, S.Y., Chen, M.C. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: A randomized placebo-controlled trial. Urology 2006, 68(5): 999-1004.
60. Van Kerrebroeck, P.E., van Voskuilen, A.C., Heesakkers, J.P. et al Results of sacral neuromodulation therapy for urinary voiding dysfunction: Outcomes of a prospective, worldwide clinical study. J Urol 2007, 178(5): 2029-34.
61. Payne, C.K., Kelleher, C. Redefining response in overactive bladder syndrome. BJU Int 2007, 99(1): 101-6.
62. Michel, M.C., Oelke, M., Goepel, M., Beck, E., Burkart, M. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn 2007, 26(2): 190-5.
63. Blaivas, J.G., Panagopoulos, G., Weiss, J.P., Somaroo, C., Chaikin, D.C. The urgency per ception score: Validation and test-retest. J Urol 2007, 177(1): 199-202.
64. Marschall-Kehrel, D., Roberts, R.G., Brubaker, L. Patient-reported outcomes in overactive bladder: The influence of perception of condition and expectation for treatment benefit. Urology 2006, 68(2, Suppl.): 29-37.
65. Tiwari, A., Naruganahalli, K.S. Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opin Investig Drugs 2006, 15(9): 1017-37.
66. Reeves, P., Irwin, D., Kelleher, C., Milsom, I., Kopp, Z., Calvert, N., Lloyd, A. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006, 50(5): 1050-7.